Skip to main content
Premium Trial:

Request an Annual Quote

Response Genetics' Q1 Revenues Increase 59 Percent

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Increased use of its ResponseDx genetic tests drove up Response Genetics' first-quarter revenues 59 percent year over year, the company said today.

The Los Angeles-based cancer molecular diagnostic test developer said that for the three months ended March 31, revenues increased to $5.9 million from $3.7 million, in part due to an 82 percent increase in revenues associated with its ResponseDx tests for colon, lung, and gastric cancers.

During the quarter, ResponseDx revenues rose to $3.1 million from $1.7 million. Revenues from its pharma business doubled to $2.8 million.

The firm's net loss was $256,891, or $.01 per share, down from $2.1 million, or $.13 per share, a year ago.

Its R&D expenses plummeted 71 percent year over year to $164,342, while SG&A costs increased 6 percent to $3.32 million.

Response Genetics ended the quarter with $4.1 million in cash and cash equivalents.

Shares of the firm's stock on the Nasdaq rose 27 percent to $2.40 in early afternoon trading.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.